DOCOSAHEXAENOIC ACID (DHA): A NUTRITIONAL VIEW FOR THE PREVENTION OF ALZHEIMER'S DISEASE

被引:0
|
作者
Valenzuela B, Rodrigo [1 ]
Bascunan G, Karla [1 ]
Valenzuela B, Alfonso [2 ]
机构
[1] Univ Chile, Escuela Nutr & Dietet, Fac Med, Santiago, Chile
[2] Univ Chile, Ctr Lipidos, INTA, Casilla 138-11, Santiago, Chile
来源
REVISTA CHILENA DE NUTRICION | 2008年 / 35卷
关键词
Neurodegenerative diseases; Alzheimer disease; beta-amiloid peptide; docosahexaenoic acid; neuroprotectin D1;
D O I
暂无
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Alzheimer's disease (AD) is a major public health problem in many countries of the world; however the specific cause of this disease is still unknown. Currently, a bulk of evidence supports the hypothesis that beta-amyloid peptide could be the cause of synaptic injuries and neuronal death observed at the initial stages of the disease. Patients with AD show lower levels of docosahexaenoic acid (DHA, C22: 6; omega-3) in plasma and brain tissue, as compared with age-matched controls. In addition, epidemiological studies indicate that a high intake of DMA may have protective properties against neurodegenerative diseases. These observations are supported by in vivo studies showing that diets rich in DHA reduce synaptic injuries and cognitive defects induced by the beta-amyloid peptide. Although the molecular basis of these neuroprotective effects are still unknown, a number of mechanisms have been proposed to explain this protection, such as: regulation in the expression of potentially protective genes, activation of anti-inflammatory pathways, and modulation of the functional properties of neuronal membranes along with changes in their structural characteristics and physical-chemical properties. The present work reviews and discusses the molecular basis of the hypothesis on the protective role of DHA in the prevention of AD. Alzheimer's disease (AD) is a major public health problem in many countries of the world; however the specific cause of this disease is still unknown. Currently, a bulk of evidence supports the hypothesis that beta-amyloid peptide could be the cause of synaptic injuries and neuronal death observed at the initial stages of the disease. Patients with AD show lower levels of docosahexaenoic acid (DHA, C22: 6; omega-3) in plasma and brain tissue, as compared with age-matched controls. In addition, epidemiological studies indicate that a high intake of DMA may have protective properties against neurodegenerative diseases. These observations are supported by in vivo studies showing that diets rich in DHA reduce synaptic injuries and cognitive defects induced by the beta-amyloid peptide. Although the molecular basis of these neuroprotective effects are still unknown, a number of mechanisms have been proposed to explain this protection, such as: regulation in the expression of potentially protective genes, activation of anti-inflammatory pathways, and modulation of the functional properties of neuronal membranes along with changes in their structural characteristics and physical-chemical properties. The present work reviews and discusses the molecular basis of the hypothesis on the protective role of DHA in the prevention of AD.
引用
收藏
页码:250 / 261
页数:12
相关论文
共 50 条
  • [1] Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease
    Quinn, Joseph
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S54 - S55
  • [2] DOCOSAHEXAENOIC ACID: ALZHEIMER'S DISEASE PREVENTION AND TREATMENT
    不详
    GERONTOLOGIST, 2008, 48 : 263 - 263
  • [3] Lysophosphatidylcholine-Docosahexaenoic acid (LPC-DHA), a novel nutraceutical for the prevention of blindness associated with Alzheimer's Disease
    Dhavamani, Sugasini
    Dhavamani, Sugasini
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (03) : S736 - S736
  • [4] Fish, docosahexaenoic acid and Alzheimer's disease
    Cunnane, S. C.
    Plourde, M.
    Pifferi, F.
    Begin, M.
    Feart, C.
    Barberger-Gateau, P.
    PROGRESS IN LIPID RESEARCH, 2009, 48 (05) : 239 - 256
  • [5] Docosahexaenoic acid and Alzheimer's disease: a reason for hope
    Florent-Bechard, Sabrina
    Youssef, Ihsen
    Malaplate-Armand, Catherine
    Koziel, Violette
    Leininger-Muller, Brigitte
    Kriem, Badreddine
    Olivier, Jean-Luc
    Oster, Thierry
    Pillot, Thierry
    OCL-OILSEEDS AND FATS CROPS AND LIPIDS, 2007, 14 (01) : 16 - 24
  • [6] Docosahexaenoic acid and Alzheimer disease
    Morris, Martha Clare
    ARCHIVES OF NEUROLOGY, 2006, 63 (11) : 1527 - 1528
  • [7] Docosahexaenoic Acid (DHA)
    不详
    ALTERNATIVE MEDICINE REVIEW, 2009, 14 (04) : 391 - 399
  • [8] Docosahexaenoic acid (DHA)
    Leger, Claude L.
    OCL-OILSEEDS AND FATS CROPS AND LIPIDS, 2007, 14 (01) : 10 - 10
  • [9] The role of docosahexaenoic acid (DHA) in the prevention of cognitive impairment in the elderly
    Bialecka-Debek, Agata
    Granda, Dominika
    Pietruszka, Barbara
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2021, 75 : 345 - 361
  • [10] Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study -Sponsored DHA Clinical Trial
    Tomaszewski, Natalie
    He, Xulei
    Solomon, Victoria
    Lee, Mitchell
    Mack, Wendy J.
    Quinn, Joseph F.
    Braskie, Meredith N.
    Yassine, Hussein N.
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 74 (03) : 975 - 990